REPLY TO QUERY FROM BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") DATED 25 NOVEMBER 2021 PERTAINING TO (I) MEMORANDUM OF UNDERSTANDING WITH RUSSIAN DIRECT INVESTMENT FUND ("RDIF") ("MOU") (II) MASTER SERVICE AGREEMENT BETWEEN UCREST BERHAD'S ("UCREST") WHOLLY OWNED SUBSIDIARY, UCREST TECHNOLOGY LIMITED, AND LIMITED LIABILITY COMPANY HUMAN VACCINE, A WHOLLY OWNED SUBSIDIARY OF RDIF ("MSA")

We refer to your Company’s announcement dated 24 November 2021, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:-

1) The date on which the Technology Transfer Agreement was entered into.
2) The names of the parties to the Technology Transfer Agreement.
3) The date of approval of the import license and the name of the approving authority.
4) The date on which the Quality Agreement was signed.
5) To clarify whether the Quality Agreement was signed by all 3 contract manufacturers that were announced by UCrest on 19 May 2021 and 9 June 2021.

6) The expected date of commencement of manufacturing of the vaccines.

Please furnish Bursa Securities with your reply within one (1) market day from the date hereof.

Yours faithfully,
Listing, 
Regulation

Cc : Market Surveillance Dept. , Securities Commission (via email)